In prostate cancer, cervical cancer, and colorectal cancer, FOXD1 is markedly up-regulated and indicates a poor prognosis of the patients; functionally, FOXD1 can promote tumor growth and metastasis [38–41]. This evidence concerns the gene FOXD1 and neoplasm.